Creating the Next Generation of Translational Geroscientists

John C. Newman, Julie L. Sokoloski, Paul D. Robbins, Laura J. Niedernhofer, May J. Reed, Jeanne Wei, Steven N. Austad, Nir Barzilai, Harvey Jay Cohen, George A. Kuchel, James L. Kirkland, Robert J. Pignolo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Advances in understanding fundamental processes of aging have led to a variety of investigational therapies to delay or prevent age-related diseases and conditions. These geroscience therapeutics hold the promise of revolutionizing medical care of older adults by treating the complex syndromes of aging and preserving health and independence. A crucial bottleneck is the study of geroscience therapeutics in early-stage, first-in-human, or proof-of-concept clinical trials. There is a limited pool of clinical investigators with the combination of knowledge and skills at the interface of clinical research, care of older adults, and aging biology needed to successfully design, fund, and implement geroscience trials. Current training pipelines are insufficient to meet the need. The sixth retreat of the National Institute on Aging R24 Geroscience Network brought together basic scientists, gerontologists, clinicians, and clinical researchers from the United States and Europe to discuss how to identify, recruit, and train investigators who can perform early-stage clinical trials in geroscience. We present herein the group's consensus on necessary subject domains and competencies, identification of candidate learners, credentialing learners, and the efficient and rapid implementation of training programs. Foundations and funding agencies have crucial roles to play in catalyzing the development of these programs. Geriatrician investigators are indispensable but cannot meet the need alone. Translational geroscience training programs can create a cadre of groundbreaking investigators from a variety of backgrounds and foster institutional cultures supportive of multidisciplinary translational aging research to turn innovative ideas into transformative therapeutics that can improve the health and independence of older adults.

Original languageEnglish (US)
JournalJournal of the American Geriatrics Society
DOIs
StatePublished - Jan 1 2019

Fingerprint

Research Personnel
National Institute on Aging (U.S.)
Clinical Trials
Credentialing
Education
Investigational Therapies
Program Development
Translational Medical Research
Health
Financial Management
Therapeutics
Research
Geriatricians

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Newman, J. C., Sokoloski, J. L., Robbins, P. D., Niedernhofer, L. J., Reed, M. J., Wei, J., ... Pignolo, R. J. (2019). Creating the Next Generation of Translational Geroscientists. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.16055

Creating the Next Generation of Translational Geroscientists. / Newman, John C.; Sokoloski, Julie L.; Robbins, Paul D.; Niedernhofer, Laura J.; Reed, May J.; Wei, Jeanne; Austad, Steven N.; Barzilai, Nir; Cohen, Harvey Jay; Kuchel, George A.; Kirkland, James L.; Pignolo, Robert J.

In: Journal of the American Geriatrics Society, 01.01.2019.

Research output: Contribution to journalArticle

Newman, JC, Sokoloski, JL, Robbins, PD, Niedernhofer, LJ, Reed, MJ, Wei, J, Austad, SN, Barzilai, N, Cohen, HJ, Kuchel, GA, Kirkland, JL & Pignolo, RJ 2019, 'Creating the Next Generation of Translational Geroscientists', Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.16055
Newman JC, Sokoloski JL, Robbins PD, Niedernhofer LJ, Reed MJ, Wei J et al. Creating the Next Generation of Translational Geroscientists. Journal of the American Geriatrics Society. 2019 Jan 1. https://doi.org/10.1111/jgs.16055
Newman, John C. ; Sokoloski, Julie L. ; Robbins, Paul D. ; Niedernhofer, Laura J. ; Reed, May J. ; Wei, Jeanne ; Austad, Steven N. ; Barzilai, Nir ; Cohen, Harvey Jay ; Kuchel, George A. ; Kirkland, James L. ; Pignolo, Robert J. / Creating the Next Generation of Translational Geroscientists. In: Journal of the American Geriatrics Society. 2019.
@article{39854ffc0f2048af9f25e91b9eca87d4,
title = "Creating the Next Generation of Translational Geroscientists",
abstract = "Advances in understanding fundamental processes of aging have led to a variety of investigational therapies to delay or prevent age-related diseases and conditions. These geroscience therapeutics hold the promise of revolutionizing medical care of older adults by treating the complex syndromes of aging and preserving health and independence. A crucial bottleneck is the study of geroscience therapeutics in early-stage, first-in-human, or proof-of-concept clinical trials. There is a limited pool of clinical investigators with the combination of knowledge and skills at the interface of clinical research, care of older adults, and aging biology needed to successfully design, fund, and implement geroscience trials. Current training pipelines are insufficient to meet the need. The sixth retreat of the National Institute on Aging R24 Geroscience Network brought together basic scientists, gerontologists, clinicians, and clinical researchers from the United States and Europe to discuss how to identify, recruit, and train investigators who can perform early-stage clinical trials in geroscience. We present herein the group's consensus on necessary subject domains and competencies, identification of candidate learners, credentialing learners, and the efficient and rapid implementation of training programs. Foundations and funding agencies have crucial roles to play in catalyzing the development of these programs. Geriatrician investigators are indispensable but cannot meet the need alone. Translational geroscience training programs can create a cadre of groundbreaking investigators from a variety of backgrounds and foster institutional cultures supportive of multidisciplinary translational aging research to turn innovative ideas into transformative therapeutics that can improve the health and independence of older adults.",
author = "Newman, {John C.} and Sokoloski, {Julie L.} and Robbins, {Paul D.} and Niedernhofer, {Laura J.} and Reed, {May J.} and Jeanne Wei and Austad, {Steven N.} and Nir Barzilai and Cohen, {Harvey Jay} and Kuchel, {George A.} and Kirkland, {James L.} and Pignolo, {Robert J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/jgs.16055",
language = "English (US)",
journal = "Journal of the American Geriatrics Society",
issn = "0002-8614",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Creating the Next Generation of Translational Geroscientists

AU - Newman, John C.

AU - Sokoloski, Julie L.

AU - Robbins, Paul D.

AU - Niedernhofer, Laura J.

AU - Reed, May J.

AU - Wei, Jeanne

AU - Austad, Steven N.

AU - Barzilai, Nir

AU - Cohen, Harvey Jay

AU - Kuchel, George A.

AU - Kirkland, James L.

AU - Pignolo, Robert J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Advances in understanding fundamental processes of aging have led to a variety of investigational therapies to delay or prevent age-related diseases and conditions. These geroscience therapeutics hold the promise of revolutionizing medical care of older adults by treating the complex syndromes of aging and preserving health and independence. A crucial bottleneck is the study of geroscience therapeutics in early-stage, first-in-human, or proof-of-concept clinical trials. There is a limited pool of clinical investigators with the combination of knowledge and skills at the interface of clinical research, care of older adults, and aging biology needed to successfully design, fund, and implement geroscience trials. Current training pipelines are insufficient to meet the need. The sixth retreat of the National Institute on Aging R24 Geroscience Network brought together basic scientists, gerontologists, clinicians, and clinical researchers from the United States and Europe to discuss how to identify, recruit, and train investigators who can perform early-stage clinical trials in geroscience. We present herein the group's consensus on necessary subject domains and competencies, identification of candidate learners, credentialing learners, and the efficient and rapid implementation of training programs. Foundations and funding agencies have crucial roles to play in catalyzing the development of these programs. Geriatrician investigators are indispensable but cannot meet the need alone. Translational geroscience training programs can create a cadre of groundbreaking investigators from a variety of backgrounds and foster institutional cultures supportive of multidisciplinary translational aging research to turn innovative ideas into transformative therapeutics that can improve the health and independence of older adults.

AB - Advances in understanding fundamental processes of aging have led to a variety of investigational therapies to delay or prevent age-related diseases and conditions. These geroscience therapeutics hold the promise of revolutionizing medical care of older adults by treating the complex syndromes of aging and preserving health and independence. A crucial bottleneck is the study of geroscience therapeutics in early-stage, first-in-human, or proof-of-concept clinical trials. There is a limited pool of clinical investigators with the combination of knowledge and skills at the interface of clinical research, care of older adults, and aging biology needed to successfully design, fund, and implement geroscience trials. Current training pipelines are insufficient to meet the need. The sixth retreat of the National Institute on Aging R24 Geroscience Network brought together basic scientists, gerontologists, clinicians, and clinical researchers from the United States and Europe to discuss how to identify, recruit, and train investigators who can perform early-stage clinical trials in geroscience. We present herein the group's consensus on necessary subject domains and competencies, identification of candidate learners, credentialing learners, and the efficient and rapid implementation of training programs. Foundations and funding agencies have crucial roles to play in catalyzing the development of these programs. Geriatrician investigators are indispensable but cannot meet the need alone. Translational geroscience training programs can create a cadre of groundbreaking investigators from a variety of backgrounds and foster institutional cultures supportive of multidisciplinary translational aging research to turn innovative ideas into transformative therapeutics that can improve the health and independence of older adults.

UR - http://www.scopus.com/inward/record.url?scp=85068715664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068715664&partnerID=8YFLogxK

U2 - 10.1111/jgs.16055

DO - 10.1111/jgs.16055

M3 - Article

C2 - 31287934

AN - SCOPUS:85068715664

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

SN - 0002-8614

ER -